›2.↳ 1The anti-CGRP antagonist antibody according to claim 1, wherein the anti-CGRP antagonist antibody binds the C-terminal fragment having amino acids 25-…d2
The anti-CGRP antagonist antibody according to claim 1, wherein the anti-CGRP antagonist antibody binds the C-terminal fragment having amino acids 25-37 of human α-CGRP.
›3.↳ 1The anti-CGRP antagonist antibody according to claim 1, wherein the anti-CGRP antagonist antibody binds a C-terminal epitope within amino acids 25-37 …d2+4
The anti-CGRP antagonist antibody according to claim 1, wherein the anti-CGRP antagonist antibody binds a C-terminal epitope within amino acids 25-37 of human α-CGRP.
›4.↳ 3The anti-CGRP antagonist antibody according to claim 3, wherein the anti-CGRP antagonist antibody binds the C-terminal fragment having amino acids 33-…d3+1
The anti-CGRP antagonist antibody according to claim 3, wherein the anti-CGRP antagonist antibody binds the C-terminal fragment having amino acids 33-37 of human α-CGRP.
›5.↳ 4The anti-CGRP antagonist antibody according to claim 4, wherein the anti-CGRP antagonist antibody binds a C-terminal epitope within amino acids 33-37 …d4
The anti-CGRP antagonist antibody according to claim 4, wherein the anti-CGRP antagonist antibody binds a C-terminal epitope within amino acids 33-37 of human α-CGRP.
›6.↳ 3The anti-CGRP antagonist antibody according to claim 3, wherein the anti-CGRP antagonist antibody binds the C-terminal epitope having amino acids 33-3…d3
The anti-CGRP antagonist antibody according to claim 3, wherein the anti-CGRP antagonist antibody binds the C-terminal epitope having amino acids 33-37 of human α-CGRP.
›7.↳ 3The anti-CGRP antagonist antibody according to claim 3, wherein the anti-CGRP antagonist antibody binds the C-terminal fragment having amino acids G33…d3
The anti-CGRP antagonist antibody according to claim 3, wherein the anti-CGRP antagonist antibody binds the C-terminal fragment having amino acids G33 and/or F37 of human α-CGRP.
›8.↳ 1The anti-CGRP antagonist antibody according to claim 1, wherein the anti-CGRP antagonist antibody is: (a) an antibody having a CDR H1 as set forth in …d2
The anti-CGRP antagonist antibody according to claim 1, wherein the anti-CGRP antagonist antibody is: (a) an antibody having a CDR H1 as set forth in SEQ ID NO: 3; a CDR H2 as set forth in SEQ ID NO: 4; a CDR H3 as set forth in SEQ ID NO: 5; a CDR L1 as set forth in SEQ ID NO: 6; a CDR L2 as set forth in SEQ ID NO: 7; and a CDR L3 as set forth in SEQ ID NO: 8; or (b) a variant of an antibody of (a) as shown in Table 6.
›9.↳ 1The anti-CGRP antagonist antibody according to claim 1, wherein the anti-CGRP antagonist antibody comprising a VH domain that is at least 90% identica…d2+1
The anti-CGRP antagonist antibody according to claim 1, wherein the anti-CGRP antagonist antibody comprising a VH domain that is at least 90% identical in amino acid sequence to SEQ ID NO: 1 and a VL domain that is at least 90% identical in amino acid sequence to SEQ ID NO: 2.
›10.↳ 9The anti-CGRP antagonist antibody according to claim 9, wherein the amino acid residue at position 99 of SEQ ID NO: 1 is L or is substituted by A, N, …d3
The anti-CGRP antagonist antibody according to claim 9, wherein the amino acid residue at position 99 of SEQ ID NO: 1 is L or is substituted by A, N, S, T, V or R, and wherein the amino acid residue at position 100 of SEQ ID NO: 1 is A, or is substituted by L, R, S, V, Y, C G, T, K or P.
›11.↳ 1The anti-CGRP antagonist antibody according to claim 1, wherein the anti-CGRP antagonist antibody comprises a VH domain comprising SEQ ID NO: 1 and a …d2
The anti-CGRP antagonist antibody according to claim 1, wherein the anti-CGRP antagonist antibody comprises a VH domain comprising SEQ ID NO: 1 and a VL domain comprising SEQ ID NO: 2.
›12.↳ 1The anti-CGRP antagonist antibody according to claim 1, wherein the anti-CGRP antagonist antibody comprises a heavy chain produced by the expression v…d2
The anti-CGRP antagonist antibody according to claim 1, wherein the anti-CGRP antagonist antibody comprises a heavy chain produced by the expression vector with ATCC Accession No. PTA-6867.
›13.↳ 1The anti-CGRP antagonist antibody according to claim 1, wherein the anti-CGRP antagonist antibody comprises a light chain produced by the expression v…d2
The anti-CGRP antagonist antibody according to claim 1, wherein the anti-CGRP antagonist antibody comprises a light chain produced by the expression vector with ATCC Accession No. PTA-6866.
›14.↳ 1The anti-CGRP antagonist antibody according to claim 1, consisting of a heavy chain sequence of SEQ ID NO: 11 and a light chain sequence of SEQ ID NO:…d2
The anti-CGRP antagonist antibody according to claim 1, consisting of a heavy chain sequence of SEQ ID NO: 11 and a light chain sequence of SEQ ID NO: 12.
›15.↳ 1The anti-CGRP antagonist antibody according to claim 1, wherein the anti-CGRP antagonist antibody comprises a heavy chain constant region derived from…d2
The anti-CGRP antagonist antibody according to claim 1, wherein the anti-CGRP antagonist antibody comprises a heavy chain constant region derived from a human IgG2 constant region.
›16.↳ 1The anti-CGRP antagonist antibody according to claim 1, wherein the anti-CGRP antagonist antibody comprises an Fc region.d2+1
The anti-CGRP antagonist antibody according to claim 1, wherein the anti-CGRP antagonist antibody comprises an Fc region.
›17.↳ 16The anti-CGRP antagonist antibody according to claim 16, wherein the Fc region comprises an impaired effector function.d3
The anti-CGRP antagonist antibody according to claim 16, wherein the Fc region comprises an impaired effector function.
›18.↳ 1The anti-CGRP antagonist antibody according claim 1, wherein the antibody is a humanized antibody.d2
The anti-CGRP antagonist antibody according claim 1, wherein the antibody is a humanized antibody.
›19.↳ 1The anti-CGRP antagonist antibody according to claim 1, wherein the anti-CGRP antagonist antibody is formulated for systemic administration.d2
The anti-CGRP antagonist antibody according to claim 1, wherein the anti-CGRP antagonist antibody is formulated for systemic administration.
›20.↳ 1A pharmaceutical composition comprising the anti-CGRP antagonist antibody of claim 1 and a pharmaceutically acceptable excipient.d2
A pharmaceutical composition comprising the anti-CGRP antagonist antibody of claim 1 and a pharmaceutically acceptable excipient.
